Direct-acting antiviral agents and the path to interferon independence

Clinical Gastroenterology and Hepatology

Volumn 12, Issue 5, 2014, Pages 728-737

  Schmidt, Warren N ^a,b   Nelson, David R ^c   Pawlotsky, Jean Michel ^d,e   Sherman, Kenneth E ^f   Thomas, David L ^g   Chung, Raymond T ^h  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c UNIVERSITY OF FLORIDA   (United States)

^d HENRI MONDOR HOSPITAL   (France)

^e INSERM U955   (France)

^f UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^g DEPARTMENT OF PATHOLOGY   (United States)

^h MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

DAA; Non nucleoside; NS3 4A Protease Inhibitor; Nucleoside Nucleotide

Indexed keywords

ABT 333; ABT 450; ANTIVIRUS AGENT; ASUNAPREVIR; BI 207127; BMS 791325; BOCEPREVIR; DIRECT ACTING DRUG; DRUG; FALDAPREVIR; INTERFERON; LEDIPASVIR; MK 0608; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; NONSTRUCTURAL PROTEIN 5A INHIBITOR; NUCLEOTIDYLTRANSFERASE INHIBITOR; PROTEINASE INHIBITOR; RIBAVIRIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; TELAPREVIR; UNCLASSIFIED DRUG; VANIPREVIR;

ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; DRUG RESPONSE; HEPATITIS C; HUMAN; IMMUNOTHERAPY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; DRUG THERAPY; HEPATITIS C, CHRONIC; PROCEDURES; TREATMENT OUTCOME; TRENDS;

ANTIVIRAL AGENTS; DRUG THERAPY; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; TREATMENT OUTCOME;

EID: 84899061811     PISSN: 15423565     EISSN: 15427714     Source Type: Journal    
DOI: 10.1016/j.cgh.2013.06.024     Document Type: Review

References (53)

1. Lindenbach B.D., Rice C.M. Unravelling hepatitis C virus replication from genome to function. Nature 2005, 436:933-938.
2. Hoofnagle J.H., Mullen K.D., Jones D.B., et al. Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon. A preliminary report. NEngl J Med 1986, 315:1575-1578.
3. Rosen H.R. Chronic hepatitis C infection. NEngl J Med 2011, 364:2429-2438.
4. Sarasin-Filipowicz M., Oakeley E.J., Duong F.H.T., et al. Interferon signaling and treatment outcome in chronic hepatitis C. Proceedings of the National Academy of Sciences of the United States of America 2008, 105:7034-7039.
5. Lemon S.M. Induction and evasion of innate antiviral responses by hepatitis C virus. JBiol Chem 2010, 285:22741-22747.
6. Thompson A.J., Muir A.J., Sulkowski M.S., et al. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology 2010, 139:120-U178.
7. Urban T.J., Thompson A.J., Bradrick S.S., et al. IL28B genotype isassociated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C. Hepatology 2010, 52:1888-1896.
8. Herrmann E., Lee J.H., Marinos G., et al. Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon. Hepatology 2003, 37:1351-1358.
9. Jain M.K., Zoellner C. Role of ribavirin in HCV treatment response: now and in the future. Expert Opin Pharmacother 2010, 11:673-683.
10. Martinot-Peignoux M., Stern C., Maylin S., et al. Twelve weeks posttreatment follow-up is as relevant as 24 weeks to determine the sustained virologic response in patients with hepatitis C virus receiving pegylated interferon and ribavirin. Hepatology 2010, 51:1122-1126.
11. Dahari H., Guedj J., Perelson A.S., et al. Hepatitis C viral kinetics in the era of direct acting antiviral agents and IL28B. Curr Hepat Rep 2011, 10:214-227.
12. Adiwijaya B.S., Hare B., Caron P.R., et al. Rapid decrease of wild-type hepatitis C virus on telaprevir treatment. Antivir Ther 2009, 14:591-595.
13. Njoroge F.G., Chen K.X., Shih N.Y., et al. Challenges in modern drug discovery: a case study of boceprevir, an HCV protease inhibitor for the treatment of hepatitis C virus infection. Acc Chem Res 2008, 41:50-59.
14. Moreno C., Berg T., Tanwandee T., et al. Antiviral activity of TMC435 monotherapy in patients infected with HCV genotypes 2-6: TMC435-C202, a phase ha, open-label study. JHepatol 2012, 56:1247-1253.
15. Everson G., Cooper C., Hezode C., et al. Rapid and sustained achievement of undetectable HCV RNA during treatment with ritonavir-boosted danoprevir/peg-IFN alpha-2a/RBV in HCV genotype 1 or 4 patients: dauphine week 12 interim analysis. JHepatol 2012, 56. S466.
16. Sarrazin C., Zeuzem S. Resistance to direct antiviral agents in patients with hepatitis C virus infection. Gastroenterology 2010, 138:447-462.
17. Nelson D.R., Zeuzem S., Andreone P., et al. Balapiravir plus peginterferon alfa-2a (40KD)/ribavirin in a randomized trial of hepatitis C genotype 1 patients. Ann Hepatol 2012, 11:15-31.
18. O'Brien C., Godofsky E., Rodriguez-Torres M., et al. Randomized trial of valopicitabine (NM283), alone or with peg-interferon, vs. retreatment with peg-interferon plus ribavirin (pegifn/RBV) in hepatitis C patients with previous non-response to pegifn/RBV: First interim results. Hepatology 2005, 42. 234a-234a.
19. Gane E.J., Roberts S.K., Stedman C.A.M., et al. Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet 2010, 376:1467-1475.
20. Susser S., Welsch C., Wang Y.L., et al. Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients. Hepatology 2009, 50:1709-1718.
21. Targett-Adams P., Graham E.J., Middleton J., et al. Small molecules targeting hepatitis C virus-encoded NS5A cause subcellular redistribution of their target: insights into compound modes of action. JVirol 2011, 85:6353-6368.
22. Gao M., Nettles R.E., Belema M., et al. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature 2010, 465:96-100.
23. Wang C.F., Huang H.C., Valera L., et al. Hepatitis C virus RNA elimination and development of resistance in replicon cells treated with BMS-790052. Antimicrob Agents Chemother 2012, 56:1350-1358.
24. Pawlotsky J.M. Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus. Hepatology 2011, 53:1742-1751.
25. Kieffer T.L., Sarrazin C., Miller J.S., et al. Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients. Hepatology 2007, 46:631-639.
26. Sarrazin C., Kieffer T.L., Bartels D., et al. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology 2007, 132:1767-1777.
27. Brainard D.M., Petry A., Van Dyck K., et al. Safety and antiviral activity of Mk-5172, a novel Hcv N53/4a protease inhibitor with potent activity against known resistance mutants, in genotype 1 and 3 HCV-infected patients. Hepatology 2010, 52:706a-707a.
28. Clark V.C., Peter J.A., Nelson D.R. New therapeutic strategies inHCV: second-generation protease inhibitors. Liver Int 2013, 33(Suppl 1):80-84.
29. Powdrill M.H., Bernatchez J.A., Gotte M. Inhibitors of the hepatitis C virus RNA-dependent RNA polymerase NS5B. Viruses 2010, 2:2169-2195.
30. Carroll S.S., Ludmerer S., Handt L., et al. Robust antiviral efficacy upon administration of a nucleoside analog to hepatitis C virus-infected chimpanzees. Antimicrob Agents Chemother 2009, 53:926-934.
31. Lawitz E.J., Gruener D., Hill J.M., et al. Aphase 1, randomized, placebo-controlled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C. JHepatol 2012, 57:24-31.
32. Jacobson I.M., McHutchison J.G., Dusheiko G., et al. Telaprevir for previously untreated chronic hepatitis C virus infection. NEngl J Med 2011, 364:2405-2416.
33. Poordad F., McCone J., Bacon B.R., et al. Boceprevir for untreated chronic HCV genotype 1 infection. NEngl J Med 2011, 364:1195-1206.
34. Sherman K.E., Flamm S.L., Afdhal N.H., et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. NEngl J Med 2011, 365:1014-1024.
35. McHutchison J.G., Manns M.P., Muir A.J., et al. Telaprevir for previously treated chronic HCV infection. NEngl J Med 2010, 362:1292-1303.
36. Muir A.J., Poordad F.F., McHutchison J.G., et al. Retreatment with telaprevir combination therapy in hepatitis C patients with well-characterized prior treatment response. Hepatology 2011, 54:1538-1546.
37. Bacon B.R., Gordon S.C., Lawitz E., et al. Boceprevir for previously treated chronic HCV genotype 1 infection. NEngl J Med 2011, 364:1207-1217.
38. Olsen D.B., Davies M.E., Handt L., et al. Sustained viral response in a hepatitis C virus-infected chimpanzee via a combination of direct-acting antiviral agents. Antimicrob Agents Chemother 2011, 55:937-939.
39. Lok A.S., Gardiner D.F., Lawitz E., et al. Preliminary study of two antiviral agents for hepatitis C genotype 1. NEngl J Med 2012, 366:216-224.
40. Chayama K., Takahashi S., Toyota J., et al. Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders. Hepatology 2012, 55:742-748.
41. Gane E.J., Stedman C.A., Hyland R.H., et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. NEngl J Med 2013, 368:34-44.
42. Osinusi A., Heytens L., Lee Y.J., et al. High efficacy of GS-7977 in combination with low or full dose ribavirin for 24 weeks in difficult to treat HCV infected genotype 1 patients: interim analysis from The SPARE Trial. Hepatology 2012, 56. 1518-1518.
43. Jacobson I.M., Gordon S.C., Kowdley K.V., et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. NEngl J Med 2013, 368:1878-1887.
44. Lawitz E., Mangia A., Wyles D., et al. Sofosbuvir for PreviouslyUntreated Chronic Hepatitis C Infection. NEngl J Med 2013.
45. Sulkowski M.S., Gardiner D.F., Rodriguez-Torres M., et al. Sustained virological response with daclatasvir plus sofosbuvir+/- ribavirin (RBV) in chronic HCV genotype (GT) 1-infected patients who previously failed telaprevir (TVR) or boceprevir (BOC). JHepatol 2013, 58:S567-S577.
46. Zeuzem S., Soriano V., Asselah T., et al. Svr4 and Svr12 with an interferon-free regimen of Bi201335 and Bi207127,+/- ribavirin, in treatment-naive patients with chronic genotype-1 HCV infection: interim results of sound-C2. JHepatol 2012, 56. S45.
47. Poordad F., Lawitz E., Kowdley K.V., et al. Exploratory study of oral combination antiviral therapy for hepatitis C. NEngl J Med 2013, 368:45-53.
48. Jacobson I.M., Sulkowski M.S., Gane E.J., et al. VX-222, Telaprevir and ribavirin in treatment-naive patients with genotype 1 chronic hepatitis C: results of the ZENITH study interferon-free regimen. Hepatology 2012, 56. 308a.
49. Kowdley K.V.L.E., Poordad F., et al. Safety and efficacy of interferon-free regimens of ABT-450/r, ABT-267, ABT-333+/- ribavirin in patients with chronic HCV GT1 infection: results from the AVIATOR study. JHepatol 2013, 58:S2.
50. Everson G., Sims K.D., Rodriguez-Torres M., et al. Interim analysis of an interferon (IFN)- and ribavirin (RBV)-free regimen of daclatasvir (DCV), asunaprevir (ASV), and BMS-791325 in treatment-naive, hepatitis C virus genotype 1-infected patients. JHepatol 2013, 58:S567-S577.
51. Lok A.S., Gardiner D.F., Hezode C., et al. Sustained virologic response in chronic HCV genotype (GT) 1-infected null responders with combination of daclatasvir (DCV; NS5A inhibitor) and asunaprevir (ASV; NS3 inhibitor) with or without peginterferon alfa-2a/ribavirin (PEG/RBV). Hepatology 2012, 56:230a-231a.
52. Zeuzem S., Soriano V., Asselah T., et al. Interferon (IFN)-free combination treatment with the HCV NS3/4A protease inhibitor BI 201335 and the non-nucleoside NS5B inhibitor BI 207127+/- ribavirin (R): final results of SOUND-C2 and predictors of response. Hepatology 2012, 56:308a-309a.
53. Lawitz E., Poordad F., Kowdley K.V., et al. A12-week interferon-free regimen of Abt-450/R, Abt-072, and ribavirin was well tolerated and achieved sustained virologic response in 91% treatment-naive HCV Il28b-Cc genotype-1-infected subjects. JHepatol 2012, 56. S7.